Vertex Pharmaceuticals Incorporated

NASDAQ:VRTX

Biotechnology

Healthcare
$536.45 -1.40%

-$6.43 today

Market cap
$136.01B
Beta
0.31
P/E (TTM)
26.5
EPS (TTM)
$17.07
52W Low $362.50High $507.92

Volume 1.29M

Average 1.26M

VRTX EBITDA Margin

EBITDA as a percentage of revenue.

Vertex Pharmaceuticals IncorporatedNASDAQ: VRTX

EBITDA Margin · Q3 FY2026 · quarter ended Sep 2026

EBITDA Margin narrows to 20.7%

EBITDA Margin was 20.7% in Q3 FY2026, down 23.4 pp from a year earlier. On a trailing-twelve-month basis it was 37.4%, down 2.3 pp year over year. Over 3 fiscal years it narrowed by 9.4 pp.

Context

  • EBITDA Margin widened in 1 of the last 3 fiscal years.

What to watch

Whether EBITDA Margin reaches the consensus estimate from 21 analysts of 54.5% for the fiscal year ending Dec 2026, up from 40.3% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterSep 2026
20.7%-22.7 pp QoQ
Last fiscal yearDec 2025
40.3%+35.9 pp YoY
LTMSep 2026
37.4%-2.3 pp YoY
EBITDA Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-23.4 pp+5.1 pp+28.5 pp
1 year+35.9 pp+14.2 pp-21.7 pp
3 years-9.4 pp+16.6 pp+26.0 pp
5 years+25.4 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA Margin history

Percent of revenue · from the income statement

Latest · FY2025
40.3%
Year-over-year change
+35.9pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA Margin vs competitors

How VRTX compares with its peers on the latest reported figures

  • VRTX's LTM Sep 2026 EBITDA Margin of 37.4% is the highest of the 11 companies compared; the peer median is -44.9%.
  • Its year-over-year change of -2.3 pp is the 7th highest of 11, against a peer median of +5.7 pp.
  • Over three fiscal years its change of -9.4 pp compares with a peer median of +106.1 pp.
VRTX Competitors Peer median
EBITDA Margin for VRTX and competitors
Company Period LTM level YoY 3-year change
VRTXVertex Pharmaceuticals IncorporatedLTM Sep 202637.4% -2.3 pp-9.4 pp
ALNYAlnylam Pharmaceuticals, Inc.LTM Jun 202624.0% +30.9 pp+106.3 pp
PTCTPTC Therapeutics, Inc.LTM Jun 202617.2% -30.5 pp+103.9 pp
SRPTSarepta Therapeutics, Inc.LTM Mar 20265.7% +10.5 pp+34.3 pp
BMRNBioMarin Pharmaceutical Inc.LTM Sep 2026-8.0% -32.9 pp+5.1 pp
BEAMBeam Therapeutics Inc.LTM Jun 2026-40.5% +584.3 pp+435.7 pp
IONSIonis Pharmaceuticals, Inc.LTM Sep 2026-49.3% -33.5 pp+8.7 pp
RAREUltragenyx Pharmaceutical Inc.LTM Mar 2026-75.2% +1.0 pp+105.9 pp
BBIOBridgeBio Pharma, Inc.LTM Jun 2026-85.7% +187.2 pp+377.1 pp
NTLAIntellia Therapeutics, Inc.LTM Mar 2026-581.9% +549.6 pp+308.9 pp
CRSPCRISPR Therapeutics AGLTM Sep 2026-1917.5% -679.9 pp+127741.9 pp
Peer median (excluding VRTX) -44.9%+5.7 pp+106.1 pp

Competitors are the stored peer set for VRTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue7.57B8.93B9.87B11.02B12.07B
Cost of Revenue904.2M1.08B1.26B1.53B1.81B
Gross Profit6.67B7.85B8.61B9.49B10.27B
Gross Margin88.1%87.9%87.2%86.1%85.0%
Research & Development3.05B2.66B3.16B3.63B3.75B
Selling, General & Admin840.1M944.7M1.14B1.46B1.75B
Operating Expenses3.89B3.54B4.78B9.72B5.51B
Depreciation & Amortization125.6M148.3M181.3M207.2M209.8M
EBITDA2.92B4.44B4.61B486.3M4.87B
EBITDA Margin38.5%49.7%46.7%4.4%40.3%
Operating Income2.78B4.31B3.83B(232.9M)4.76B
Operating Margin36.7%48.2%38.8%-2.1%39.4%
Interest Income4.9M144.6M614.7M598.1M490.9M
Interest Expense61.5M54.8M44.1M30.6M13.3M
Other Income / Expenses(51.7M)(75M)547.8M481.4M(117.5M)
Income Before Tax2.73B4.23B4.38B248.5M4.64B
Pre-Tax Margin36.0%47.4%44.4%2.3%38.5%
Income Tax Expense388.3M910.4M760.2M784.1M690M
Net Income2.34B3.32B3.62B(535.6M)3.95B
Net Margin30.9%37.2%36.7%-4.9%32.7%
EPS (Basic)9.0912.9714.05(2.08)15.46
EPS (Diluted)9.0112.8213.89(2.08)15.32
Weighted Avg Shares257.7M256.1M257.7M257.5M255.7M
Weighted Avg Shares (Diluted)259.9M259.1M260.5M257.9M258M

Vertex Pharmaceuticals Incorporated

NASDAQ:VRTX

Intrinsic Alpha fair value

Locked

Current Price

$536.45

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.